Fast development of high quality material - From medicinal chemistry programme to GLP tox studies material

OSD

Aprea recently submitted an IND application for APR-548 - an important milestone in their development efforts.

In collaboration with Recipharm they went through an incredibly fast process, from the start of the medicinal chemistry programme to delivery of kilogram quantities formulated for GLP toxicology studies, the overall research and development activity spanned approximately three years. Seamless transfer of analytical methods and knowledge about the compound to Recipharm’s development site in Solna enabled rapid pharmaceutical development of the phase I formulation and subsequent manufacture of clinical trial material (CTM).

First Name

Last Name

Company

Where are you based?

State/Province

I agree that Recipharm registers the above information and gives me information about services and products via email. Read more about our Privacy Policy

Hidden OSD

Hidden SFF

Hidden ADS

Hidden BU not set